Company: ARVN
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001655759-25-000075
Chunk: 48

Company: ARVINAS, INC.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 48
---
4.

(4) Dr. Berkowitz was appointed as our Chief Medical Officer effective March 18, 2024.

(5) Dr. Cacace was appointed as our Chief Scientific Officer effective June 17, 2024. Dr. Cacace had a 2024 annualized base salary of $431,826 until she was named as our Chief Scientific Officer effective June 17, 2024 at which time her base salary was increased by approximately 12.3% to $485,000, due to her change in role and significant increase in duties and responsibilities, and such salary was retroactive to May 17, 2024.

(6) Dr. Taylor served as our Chief Scientific Officer until June 17, 2024, at which time he was appointed as our President of R&D. Dr. Taylor had a 2024 annualized base salary of $466,856 until he was named President of R&D, effective June 17, 2024 at which time his base salary was decreased by approximately 48.5% to $250,000.

Annual Cash Bonuses

Our annual cash incentive program promotes and rewards our executive officers for the achievement of key business and strategic goals. Under this program, cash incentive awards are determined by multiplying each executive officer’s annualized base salary by a target annual bonus percentage and a corporate performance achievement factor established by our board of directors and compensation committee based on our performance as measured against our pre-established corporate goals. For the year ended December 31, 2024, the target annual bonus, as a percentage of base salary was 60% fo r Dr. Houston and 45% for each of Dr. Berkowitz, Mr. Cassidy, Mr. Saik and Dr. Taylor. Dr. Berkowitz’s and Mr. Saik’s total bonus amount was prorated based on their respective date of hire. Dr. Teel had an individual bonus target of 40% of his base salary until he was appointed as our Chief Business Officer, effective April 21, 2024, at which time his individual bonus target was increased to 45% of his base salary, and his total 2024 bonus amount was prorated accordingly. Dr. Cacace had an individual bonus target of 40% of her base salary until she was appointed as our Chief Scientific Officer, effective June 17, 2024, at which time her individual bonus target was increased to 45% of her base salary. As such,